Skip to search formSkip to main contentSkip to account menu

Fraxiparin

Known as: Fraxiparine 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Nadroparin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Significantly inhibitory effects of low molecular weight heparin (Fraxiparine) on the motility of lung cancer cells and its related mechanism
Low molecular weight heparin (LMWH) improving the cancer survival has been attracting attention for many years. Our previous… 
2002
2002
Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of low molecular weight heparin. Gynecological ward retrospective analysis.
2002
2002
Electrocardiographic findings and global coronary risk assessment.
ment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from… 
2000
2000
Use of low molecular weight heparin for prevention of deep vein thrombosis in total knee arthroplasty--a study of its efficacy in an Asian population.
INTRODUCTION The aims of this paper were to study the incidence of deep vein thrombosis following total knee replacement in an… 
1997
1997
Thrombospondin, a negative modulator of megakaryocytopoiesis.
1997
1997
Calcifying panniculitis in a child after renal transplantation.
Subsequently he was treated with regular kidney failure, chronic; low-molecular-weight heparin haemodialysis for 17 months with… 
1996
1996
low molecular weight heparin, nadroparin (Fraxiparine), inhibits thrombin‐induced platelet shape change and does not enhance spontaneous platelet aggregation
Therapeutic concentrations, added in vitro, of a low molecular weight heparin (LMWH), nadroparin (Fraxiparine), inhibit thrombin… 
1995
1995
Effect of the low molecular weight heparin/non steroidal anti-inflammatory drugs association on an experimental thrombosis induced by laser.
1994
1994
Suitability of low-molecular-weight heparin(oid)s and a pentasaccharide for an in vitro human thrombosis model.
There is much interest in in vitro thrombosis systems using exclusively human materials for evaluating new drugs. We have… 
1992
1992
Ex vivo activity of heparin is not predictive of blood loss after neutralization by protamine.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)